SCHEMBL7004569

SCHEMBL7004569

O=c1c2c[nH]nc2ncn1Cc1cccnc1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
POLB P06746 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.51
PKM P14618 2/20 0.51
HSD17B10 Q99714 2/20 0.51
LMNA P02545 1/20 0.51
HTT P42858 1/20 0.51
CNOT7 Q9UIV1 1/20 0.49
ROCK2 O75116 1/20 0.44
ALOX5 P09917 1/20 0.44
DHPS P49366 2/20 0.44
GRK2 P25098 4/20 0.42
GRK1 Q15835 2/20 0.42
GRK5 P34947 1/20 0.42
KDM4C Q9H3R0 1/20 0.41
MAPK10 P53779 1/20 0.41
GABRA5 P31644 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7002674 0.85 GRK2 (0.52) KDM4EL3MBTL1POLBSMN1; SMN2LMNA
SCHEMBL7003741 0.84 KDM4E (0.49) KDM4EL3MBTL1HSD17B10CNOT7ROCK2
SCHEMBL7003110 0.79 TP53 (0.53) PKMLMNA
SCHEMBL7004560 0.78 SMN1; SMN2 (0.52) KDM4EL3MBTL1SMN1; SMN2PKMLMNA
SCHEMBL7002562 0.77 KDM4E (0.53) KDM4ESMN1; SMN2PKMHSD17B10LMNA
SCHEMBL7002957 0.75 KDM4E (0.47) KDM4EPOLBHTTCNOT7GRK2
SCHEMBL7002186 0.74 TSHR (0.45) KDM4EL3MBTL1POLBLMNAHTT
SCHEMBL7004474 0.73 ALDH1A1 (0.51) KDM4EPOLBSMN1; SMN2HSD17B10LMNA
SCHEMBL7002396 0.73 SMN1; SMN2 (0.62) KDM4EL3MBTL1POLBSMN1; SMN2LMNA
SCHEMBL12761304 0.72 RAB9A (0.40) SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030186997-A1 2,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonsulsive action and methods for producing the same ELBION AG (DE) 2003-10-02 US claimed
US-20030186997-A1 2,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonsulsive action and methods for producing the same ELBION AG (DE) 2003-10-02 US disclosed
EP-1311510-A1 2,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES WITH AN ANTICONVULSIVE ACTION AND METHODS FOR PRODUCING THE SAME ARZNEIMITTELWERK DRESDEN GMBH (DE) 2003-05-21 EP disclosed
WO-2002018387-A1 2,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES WITH AN ANTICONVULSIVE ACTION AND METHODS FOR PRODUCING THE SAME ELBION AG (DE) 2002-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186997-A1 2,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonsulsive action and methods for producing the same DDO, GRIN3A, GRIK4 KDM4E 1874/4885L3MBTL1 4609/4885POLB 1373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.